Phase III Data ENLIVEN Pexidartinib’s Prospects But Liver Tox An Issue?

Phase III results for Daiichi Sankyo’s pexidartinib presented at ASCO provide new hope in a rare tumor type with no approved therapies, but hepatic toxicity also emerged as a safety issue in the study.